Shares of Pharmos shot up on mixed data for its postoperative pain drug. The intravenous cannabinor demonstrated an ability to reduce pain in comparison with a placebo in a low-dose, 12 mg section of the Phase IIa trial but failed at a 24 mg dose. "This is an unexpected pattern of results and the company continues to explore possible explanations," said the company. It was good enough for investors, though, who bid up the company stock by 35 percent.
- see this summary on the data
- read the AP report for more
Related Articles:
Pharmos pain drug fails in Phase II. Report
FDA approves synthetic cannabis. Report
Elkan Gamzu takes lead at Pharmos. Report